NCCN PROSTATEClinical Risk Stratification
Prognostic Grouping
Defining Factors
- T-Stage: Clinical stage (T1c to T4)
- PSA: Serum PSA level
- Gleason: Biopsy Grade Group (1-5)
- Biopsy Cores: Percentage of positive cores
Risk Profile
Low
Management Outlook
Low risk group. Active surveillance is often the preferred management strategy.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
Clinical Use
Used immediately following a positive prostate biopsy.
Guides the necessity of systemic staging imaging (e.g., PSMA PET/CT or bone scan) to rule out metastasis.
Directs the definitive management strategy (Surgery vs. Radiation vs. Surveillance).
How it Works
Risk Strata Definitions
| Category | Criteria (T-Stage / Grade / PSA) |
|---|---|
| Very Low Risk | T1c AND Grade Group 1 AND PSA < 10 AND < 3 positive cores (< 50% core involvement) |
| Low Risk | T1-T2a AND Grade Group 1 AND PSA < 10 |
| Favorable Intermediate | 1 intermediate factor (T2b-T2c, Grade Group 2, PSA 10-20) AND < 50% positive cores |
| Unfavorable Intermediate | Grade Group 3 OR ≥ 2 intermediate factors OR ≥ 50% positive cores |
| High Risk | T3a OR Grade Group 4/5 OR PSA > 20 |
| Very High Risk | T3b-T4 OR Primary Gleason 5 OR > 4 cores with Grade Group 4/5 |
Clinical Pearls
Management Implications
Very Low & Low Risk: Active Surveillance is the strongly preferred standard of care. Definitive treatment often results in overtreatment and unnecessary sexual/urinary toxicity.
Intermediate Risk: Favorable intermediate patients may still qualify for Active Surveillance or monotherapy (Surgery OR Radiation alone). Unfavorable intermediate requires definitive therapy, often adding short-course Androgen Deprivation Therapy (ADT) (4-6 months) if radiation is chosen.
High & Very High Risk: Systemic staging with PSMA PET is mandatory. Treatment requires multimodality approaches, typically External Beam Radiation Therapy (EBRT) combined with long-course ADT (18-36 months) and potentially abiraterone, or radical prostatectomy with extended pelvic lymph node dissection.
The Evidence
Key Reference
Prostate Cancer
NCCN Guidelines • National Comprehensive Cancer Network. Current Version;Clinical Practice Guidelines
Last Comprehensive Review: 2026